The import of penicillins and streptomycins in dosage forms to China has shown a consistent upward trend from a value of 197.16 million USD in 2024 to a forecasted value of 220.97 million USD by 2028. This upward trajectory indicates growing demand or increased consumption of these antibiotics in China over the forecast period. Although specifics for 2023 are not provided, the data suggests the year-over-year growth fluctuates slightly but remains steady around 3% annually from 2024 to 2028. The compound annual growth rate (CAGR) over these five years reflects this continuous moderate increase.
Future trends to watch for include:
- Potential policy changes in China affecting pharmaceutical imports.
- Shifts in local production capacity for antibiotics impacting import reliance.
- Global supply chain adaptations due to geopolitical dynamics.
- Evolving public health needs possibly driving demand for antibiotics.
